Adicet Bio, Inc.
ACET- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001720580
No open-market purchases or sales by Adicet Bio, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $52.8M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:57 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $116.8M (2021.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 6, 2025 | Jan 24, 2024 | Mar 15, 2023 | Mar 15, 2022 |
| Revenue | $5.78M | $10.7M | – | – | – |
| Operating expenses | $122.1M | $127.6M | $152.0M | $97.5M | $71.2M |
| Research and development | $99.1M | $99.3M | $106.0M | $71.2M | $48.9M |
| Selling, general and administrative | $23.0M | $28.3M | $26.5M | $26.3M | $22.2M |
| Operating income | -$122.1M | -$127.6M | -$152.0M | -$72.6M | -$61.4M |
| Interest expense | $36.0K | $4.00K | $25.0K | $80.0K | $176.0K |
| Income tax | $0 | $0 | $0 | $0 | -$125.0K |
| Net income | -$116.8M | -$117.1M | -$142.7M | -$69.8M | -$62.0M |
| EPS, basic | $-16.95 | $-1.33 | $-3.31 | $-1.70 | – |
| EPS, diluted | $-16.95 | $-1.33 | $-3.31 | $-1.70 | – |
| Weighted shares, basic | 6.89M | 87.9M | 43.0M | 41.1M | – |
| Weighted shares, diluted | 6.89M | 87.9M | 43.0M | 41.1M | – |
| Margins and growth | |||||
| Operating margin | -2113.8% | -1191.1% | – | – | – |
| Net margin | -2021.9% | -1093.2% | – | – | – |
| Revenue growth, year over year | −46.1% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 6, 2025 | Jan 24, 2024 | Mar 15, 2023 | Mar 15, 2022 |
| Cash and equivalents | $38.9M | $56.5M | $159.7M | $257.7M | $277.5M |
| Total current assets | $160.9M | $180.1M | $162.3M | $261.0M | $282.4M |
| Property, plant and equipment | $16.5M | $22.5M | $26.8M | $28.7M | $14.6M |
| Goodwill | – | – | $0 | $19.5M | $19.5M |
| Total assets | $192.4M | $220.2M | $207.3M | $330.7M | $338.9M |
| Accounts payable | $4.74M | $4.83M | $2.63M | $4.40M | $3.26M |
| Total current liabilities | $21.5M | $19.4M | $19.3M | $19.7M | $16.3M |
| Total liabilities | $33.1M | $33.6M | $37.1M | $38.4M | $35.8M |
| Shareholders' equity | $159.2M | $186.6M | $170.2M | $292.3M | $303.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 12, 2026 | Mar 6, 2025 | Jan 24, 2024 | Mar 15, 2023 | Mar 15, 2022 |
| Operating cash flow | -$95.2M | -$92.4M | -$93.7M | -$44.8M | -$51.1M |
| Capital expenditures | $1.74M | $1.12M | $4.46M | $16.8M | $13.0M |
| Free cash flow | -$97.0M | -$93.5M | -$98.2M | -$61.5M | -$64.1M |
| Depreciation and amortization | $6.38M | $6.47M | $6.10M | $2.58M | $1.54M |
| Stock-based compensation | $14.3M | $22.2M | $20.3M | $17.1M | $12.5M |
| Investing cash flow | $2.39M | -$119.2M | -$4.46M | -$16.8M | -$2.80M |
| Financing cash flow | $75.2M | $111.3M | $236.0K | $41.5M | $242.7M |
| Net change in cash | -$17.6M | -$100.3M | -$97.9M | -$20.0M | $188.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 247.0% | 207.5% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 3, 2026 | 9.36M | −93.9% | SEC |
| Aug 3, 2026 | 9.36M | −88.8% | SEC |
| May 19, 2026 | 9.35M | −88.7% | SEC |
| May 11, 2026 | 9.35M | −88.7% | SEC |
| Mar 10, 2026 | 9.60M | −88.4% | SEC |
| Nov 3, 2025 | 153.3M | +86.0% | SEC |
| Aug 5, 2025 | 83.3M | +1.0% | SEC |
| May 2, 2025 | 82.7M | +0.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.